Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
d0lphint0m- If you have the time and considering the holiday being over Tues, could you update it after tomorrows close or Wed? I'm really curious how much of the equity research exposure will play into this week. And curious if there's a build on the accumulation action. I've talked to a few in the biz and are buyers but still the $2 holds them back. A few will buy into privately held accounts, only to test the waters, not much. But all agree if CYDY does a press or conference that elaborates on this $2+ for up list, a confident doable plan are in for more through their brokers at up list. Most cannot believe the data results, low viral loads, no side effects, at home once a week injection, no pills and Sheen on it. Big eye catcher. But all love the opportunity to have a disruptive play in such an international issue as HIV vs some very large competition. They get it. Also, none expressed a concern to wait for market because then they're just in with the masses.
Thanks in advance if you have time,
Chump
5Top, Misiu, have a good night. Ibalizumab isn't a factor here. Dr P made that clear. Us getting over $2 and up listing is the goal.
Here's to Tues $1.20's+...no pressure D0plphin. lol
Chump
Same here 5Top. Enjoy tomorrow. Tues will be different for CYDY.
I expect a follow up from CYDY on his posted interview, ASM, equity research and hopefully some new data from the FDA. If not the next week. They know they have an August 26 deadline to exercise a r/s but won't instead have a conference call that reassures investors they have what the need to get to $2 before deadline.
Thanks for your contributions.
Chump
Maybe Immodium will buy Ibalizumab out. lol
Chump
5Top your certainly doing your DD. I admire that. My last post shows Ibalizumab about as bad as Haart. I think Pro 140 will get the show.
Chump
Heres a good one. 2015 I believe.
https://aidsinfo.nih.gov/drugs/511/ibalizumab/0/professional
"Dosing: 24-week, open-label, single-arm study:
“Control period” (Days 0-6): Participants will be monitored on their current failing ART regimen (or no therapy if the participant failed therapy and discontinued treatment within 8 weeks prior to screening).
“Essential monotherapy period” (Days 7-13): Participants will continue their current failing ART regimen (or no therapy) and will receive a single loading dose of IV ibalizumab 2000 mg on Day 7"
but
"Adverse Events
The most common treatment-emergent adverse events occurring in a Phase IIb trial (NCT00784147) were rash, diarrhea, headache, and nausea. Most events were mild to moderate. No drug-related deaths, serious adverse events, or discontinuations occurred. Laboratory and vital sign abnormalities were determined not to be clinically relevant.1"
Not sure if this is what you guys are looking for or discussing but theres plenty more out there if you google ibalizumad and monotherapy
http://www.ncbi.nlm.nih.gov/pubmed/20639524
" Early clinical trials have demonstrated significant antiviral efficacy with a >1 log(10) reduction in viral load when given as monotherapy.'
https://clinicaltrials.gov/ct2/show/NCT02475629
"Days 7-13 of the study will be an "essential monotherapy period." During Days 7 through 13 patients will continue on current failing therapy and receive one 2000 mg dose (loading dose) of ibalizumab on Day 7. Day 7 is Baseline for the treatment period (Day 7-Week 25)"
http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-4
"n IV form of PRO 140 tested as monotherapy in HIV-1 subjects with only R5 virus detectable [96] demonstrated potent and prolonged antiviral activity, with a 1.83 log10 mean reduction in HIV-1 RNA and safety relative to placebo"
http://www.ncbi.nlm.nih.gov/pubmed/24144896
"RESULTS:
Dose-proportional increases in drug exposure were observed in healthy and HIV-1-infected subjects. In healthy subjects, pharmacokinetic variability was low following single or repeat dosing (coefficient of variation, 13%-34% and 15%-23%, respectively). Mean plasma half-life was 31.5 hours. GSK1265744 monotherapy significantly reduced plasma HIV-1 RNA from baseline to day 11 in HIV-1-infected subjects receiving 5 or 30 mg versus placebo (P < .001); mean decrease was 2.2 to 2.3 log10 copies/mL, respectively. Study drug was generally well tolerated with no clinically relevant trends in laboratory values, vital signs, or electrocardiograms."
You also. I won't report you!
Get to $2 and hold for 5 days. IMO after the equity research was released their private investors knowing above 2$ or below because an up list will follow and buy. Hopefully a road show will to follow up on equity release.
Chump
5Top- I wish I could help more but i think reaching out to equity is the best source. I appreciate your posts and intuition.
Chump
5Top- take the math out of it now cause I think the message is get in now its about to blow the math will show itself later. That I don't think they can say but is the msg.
Chump
I updated the post- I think they are correct in their language but you can still email to see. Good post
5Top- These initiatives come out all the time in many many industries. I'm sure the recipients mailboxes are full of them. IMO I think the
"If achieved, the price target of $3.40 suggests potential upside of 211.9% from the recent price of $1.09 on June 28, 2016."
Probability is if all goes as CYDY has presented to them and if achieved we value it at $3.40. All the other data suggests upside from there.
Not a disclaimer but insight to what's been told we value here, read the data and if continued success will be higher.
Meaning, $3.40 now anything else is upside from the potential results CYDY has given us
is just the meat and potatoes that the recipients really want to know. Because they get em from all industries and to be able to comprehend data from, metals, shipping, buy outs etc is overwhelming to know all.
Chump
5Top- These initiatives come out all the time in many many industries. I'm sure the recipients mailboxes are full of them. IMO I think the
"If achieved, the price target of $3.40 suggests potential upside of 211.9% from the recent price of $1.09 on June 28, 2016."
is just the meat and potatoes that the recipients really want to know. Because they get em from all industries and to be able to comprehend data from, metals, shipping, buy outs etc is overwhelming to know all.
Chump
5Top- I agree this is a current target price with inclusions that reflect an investor opportunity for a higher price based on possible new events/ data etc that the company has in play. Basically, we value this at 3.40 but
if results continue as they have we believe market share etc is worth more in the near future. Consider it now than later, we believe it will pick up a considerable share of the current market for HIV treatment.
Chump
Inoviorulez- I wish you got it because I'm thinking we will be on a steady climb to the magic $2 then some surges. Maybe down a couple 3 cents in the am's and then the buyers will take it back up like today. Were held down by flippers for awhile/ which by Dolphins accumulation TA will overcome them. Also this initiative report and what will follow it IMO makes it a buy anywhere under $2. I said before in a post, these reports are always followed up with supportive news. Finally, I've said over and over again this is disruptive to whats available for HIV patients. The FDA will move quickly with it and the high end investors love anything that beats the competition.
I will be shocked if CYDY doesn't have a follow up explanation/research initiative strategy for organically up listing in the next week or so.
Have a good 4th.
Chump
D0lphin- I've been on message boards for many many years and have some good friends I share your IHub TA's with that are TA folks themselves and tell me they lurk on CYDY Ihub now for them. Your CYDY chart analysis are on the money they say. Please keep sharing them especially next week when the Vol and SP picks up. 53 years is remarkable and invaluable to us here.
Here's to $2 and up listing very soon. And more great data/patient results.
Chump
5Top- you might be on to something or theres an explanation I certainly can't contribute to. I suggest contacting
Ajay Tandon
SeeThruEquity
info@seethruequity.com
Good post!
Chump
Very good point. Very typical after Equity research initiated that a company quickly comes out with stellar news that further supports the price prediction which for CYDY was $3.40. I think you might be on to something Misiu for next week.
Chump
Thanks D0lphin, makes think about buying out the $1.10.
Seriously!
Chump
Now thats a stairway to heaven chart. Nice!
No question in my mind you've been doing this for a long time.
Looks like CYDY will break out soon to new territory. Meaning it's building and about to boom! Next week should be a edge of the seat week. Can't wait.
Thanks
Chump
On Topic- Alright does anyone think we can make it to $1.15 today?
Would be nice but the vol has to pick up.
Chump
drryan- you said, "5. Enjoy the 4th of July and understand this baby is going to be all over the news soon. Why it has not moved is 78,000 stock brokers can not buy it!!!! for their clients until it is uplisted."
Wow! good major point! Basically means it's a steal under $2.
Chump
I like that. Now if we can chew through this 1.08..which I think will happen.
Glad to see your posts.
Thanks
Chump
buckysherm- you are right, waiting on the ASM was a piece of the puzzle. ASM gave us peer exposure something CYDY hadn't had other than their normal PR's. It just happened a week or so ago. Next step is to take that data/ recognition ASM gave them and go to a reputable institutional PR firm that further spreads that info to a higher level of investors. Next step is to provide for positive data that the PR firm can share with other than retailers that "hey there's a disruptive treatment for HIV" at a lower cost, more patient friendly and absolutely a large market share to be taken from the competition. That's what high end investors look for. A start up that can capture billions in market share and being informed early. This will get us to $2 organically vs doing a r/s for the sake of just up listing.
IMO- $2 will be hit before August 26th deadline. It could take one conference call or PR elaborating on this and it's off to the races, up listed and in much deeper pockets.
Thanks for your posts!
Chump
"SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors."
Obviously the research will be distributed to the above. Certainly a potential catalyst for the SP.
Chump
Blane- from the Equity Research... "SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased."Bluehorse was correct.
Chump
Thanks Misiu- Your contributions on the trials/data and what to look into have helped me with my DD. The ASM was a success. You know it takes time for colleagues to go over what was published today. I feel the dominoes are going to fall. I'm long and convinced this is a better alternative vs current. Let's wait and see what the FDA thinks of all this. Once again, there move.
Chump
Chumps tea leaves. $2 organically no R/S.
d0lphin, pardon me but let me be the Huckleberry here. Closet, years out for $2-3? We'll have orphan status, BTD, partnership and up listed well before that. IMO- before years out if not sooner.
Bluehorse, I agree enough and thanks! Over for me.
Chump
I'll start with your posts
Scottsmith- I owe you an apology I meant Closet.
Chump
d0lphinn0m- I really looking forward to the latter of next week and week of the 11th when vol picks up for what your tea leaves will show.
Thanks!
Closet- what intrigues me the most is you differ in opinion with most on this board how CYDY is progressing but yet you are invested in the same stock suggesting much lower pps opportunities. Yes they probably paid for the coverage. That's absolutely a must for a breakthrough technology to do this. Absolutely normal to pay a top reptable research coverage to get your story out but only when you have data to back it up. It's disruptive and CYDY needs to get the science to the peers for validation. This is a catalyst for it. As for the ASM "disastrous" they were selected and peer selected over everyone else. I remember qualcomm $3, silicon investor posters from nokia, erickson etc all knocking CDMA on the msg board. Stop and take look at your phone now. Glad I held on. I see the same play here. CYDY is disruptive to whats currently available for HIV treatment. Maybe you should direct your concerns to the FDA that's validating these results and allowing further research or maybethe equity research firm. I respect Drs/scientists have to be skeptics always asking why but to overlook the phase trial extensions is far to skeptic. As for the PPS today, it's against SEC for CYDY to post this on their web. It's a holiday week end coming, vol was low meaning word has not spread yet. Give it a week and I hope you re-think your potential investment here. I won't get into Lupus and HIV but read some of the past results of patients on Pro 140. Finally, call Charlie and ask him how he feels vs his previous treatments. To have someone in a trial in just a few months speaking of the benefits vs competition is huge. Trials are usually so private. Thank you Charlie!.
Chump
I like todays action. Low vol meaning the word hasn't spread. And for them to do a coverage as they did today they must realize some better data/info will follow. They don't do one time press shots. Their reputation is for growth/new opportunities not speculation.... regardless of their disclaimer. Everyone has a disclaimer these days. Even one on CYDY's site but we've bought the stock. I expect some follow up from CYDY that backs this up. Importantly data and results/FDA responses etc to come out. This week with the holidays everyone like Scottsmith in the Hamptons (hampton Inn) later next week should pick up. Looking forward to it.
Chump
How bout a sticky for the board?
Can someone put this on twitter. I don't have a twitter acct.
Thanks
http://finance.yahoo.com/news/seethruequity-initiates-coverage-cytodyn-inc-130000282.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZANmc3Jlb2twYm5hOHFzBGcDZFhWcFpEeHVjejQzWWpZNVpHWm1NQzAyWmpNMExUTXlOV1F0WVRVMFpTMWtZMlJtTkRObU1HWTVZamc4Wm1sbGJHUStZM2xrZVE9PQRsYW5nA2VuLVVTBG9yaWdfbGFuZwNlbgRvcmlnX3JlZ2lvbgNVUwRwb3MDMARyZWdpb24DVVMEc3ltYm9sA0NZRFk-?.tsrc=applewf
d0lphin which # to be sure?
Most important. With this kind of coverage initiated, many, many and any broker can distribute the report and among their colleagues. And CYDY can use it to approach institutions, kinda like a road show. lol
Chump
no its there